Zentalis Pharmaceutical Studies on Partial Clinical Hold Following Deaths
By Adriano Marchese
Zentalis Pharmaceuticals said the Food and Drug Adminstration has temporarily halted a number of studies for its cancer treatment following two deaths in one of them.
The clinical-stage biopharmaceutical said it has placed a partial clinical hold on studies for its drug, Azenosertib.
In particular, the holds were applied to the phase 1 ZN-c3-001 dose-escalation study in solid tumors, the phase 2 ZN-c3-005 study in platinum-resistant ovarian cancer, and the phase 2 ZN-c3-004 study in uterine serous carcinoma.
Chief Executive Kimberly Blackwell said the company is working with regulators to resolve the partial clinical hold as quickly as possible.
"Over 500 patients have been treated with Azenosertib monotherapy to date, and we believe that our data indicate a favorable therapeutic index that could potentially offer meaningful benefits," Blackwell said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
June 18, 2024 07:46 ET (11:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks